Brief: Liminal BioSciences Announces Sale Of Priority Review Voucher For $105 Mln
09/08/2021 12:40
Aug 9 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES ANNOUNCES SALE OF PRIORITY REVIEW
VOUCHER
FOR $105 MILLION
* LIMINAL BIOSCIENCES INC - UNIT PROMETIC BIOTHERAPEUTICS
ENTERED
INTO A DEFINITIVE AGREEMENT TO SELL ITS RARE PEDIATRIC DISEASE
PRIORITY REVIEW VOUCHER
* LIMINAL BIOSCIENCES INC - PRV WAS GRANTED BY U.S. FDA
WITH
APPROVAL OF RYPLAZIM
Source text for Eikon: ID:nPn4bfpvLa
Further company coverage: LMNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liminal BioSciences
See all newsBrief: Liminal Biosciences Announces Completion Of The Plan Of Arrangement With Structured Alpha Lp
Brief: Liminal Biosciences Files Amended Schedule 13E-3 And Supplement To Management Information Circular
Brief: Liminal Biosciences Obtains Interim Order For Proposed Arrangement With Structured Alpha Lp
U.S. STOCKS ON THE MOVE-Liminal Biosciences, Tesla, Quad/Graphics
U.S. STOCKS ON THE MOVE-T2 Biosystems, GoodRx Holdings, ShiftPixy